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PROLONGED PERIODS OF SKELETAL muscle inactivity due to spaceflight, bed rest, or limb immobilization result in muscle atrophy in both animals and humans. Due to both the invasive nature of human muscle biopsies and the desire to use pharmacological interventions not approved for humans, animal models are commonly used to explore the mechanisms responsible for disuse atrophy, with hindlimb immobilization (i.e., casting) of rodents often used to mimic human limb immobilization (19) .
Disuse skeletal muscle atrophy results from both decreased protein synthesis and increased protein degradation, with degradation playing a major role (28) . Four major proteolytic systems [autophagy, the ubiquitin protease system (UPS), calpains, and caspase-3] are active during atrophy in skeletal muscle (19) . However, the degree to which each system contributes to disuse atrophy remains debatable. It has been argued that the UPS plays a dominant role during inactivity-induced muscle atrophy because the UPS is responsible for degrading most sarcomeric proteins (7, 16) . Nonetheless, the UPS cannot degrade intact actin and myosin because of the closely packed arrangement of these proteins in the sarcomeres of striated muscle (6, 27) . Therefore, the UPS may not be the rate-limiting step in muscle atrophy, as release of myofilaments could be a prerequisite for proteasome-mediated degradation of both actin and myosin.
Calpain and caspase-3 are two proteases that may assist the UPS by releasing myofilaments. For example, calpain can degrade the structural proteins ␣-II-spectrin (␣-fodrin), titin, and nebulin (9) . Breakdown of these cytoskeletal proteins releases actin and myosin from sarcomeres, allowing musclespecific E3 ligases to ubiquitinate myofilament proteins, targeting them for degradation by the UPS. Furthermore, caspase-3 has been reported to degrade intact actomyosin (6) . Nonetheless, definitive evidence that calpain and/or caspase-3 plays a required role in limb disuse muscle atrophy does not currently exist. Indeed, disagreement exists regarding the role that calpain plays in disuse-induced atrophy in limb muscles (24, 29) , and incomplete data are available regarding the part that caspase-3 plays in limb muscle atrophy (18) .
Recent work in mechanical ventilation-induced diaphragm atrophy suggests that a regulatory "cross talk" exists between calpain and caspase-3 in respiratory muscles. Indeed, inhibition of calpain prevented caspase-3 activation in the diaphragm during mechanical ventilation, suggesting that calpain regulates caspase-3 activity. Caspase-3 inhibition also prevented calpain activation, demonstrating caspase-3 regulation of calpain activity (17) . Nevertheless, mechanical ventilation-induced diaphragmatic atrophy is an unusually rapid and unique type of muscle atrophy, and it remains unclear if this same regulatory cross talk between calpain and caspase-3 exists in limb skeletal muscles during immobilization-induced atrophy (10, 12) . Therefore, because of limited knowledge regarding the role that calpain and caspase-3 play in disuse atrophy in limb skeletal muscles, these experiments were designed to achieve two goals: 1) to determine whether inhibition of calpain or caspase-3 is sufficient to protect against immobilization-induced limb muscle atrophy; and 2) to determine whether a regulatory cross talk exists between calpain and caspase-3 in limb skeletal muscle. We hypothesized that both calpain and caspase-3 play important roles in disuse limb muscle atrophy, and that a regulatory cross talk exists between these two proteases. Our findings support these hypotheses and demonstrate, for the first time, that both calpain and caspase-3 play a required role in inactivity-induced atrophy of limb muscle. Furthermore, our results also reveal that a calpain/ caspase-3 regulatory cross talk exists in limb skeletal muscle whereby calpain can promote caspase-3 activation, and active caspase-3 can induce calpain activation in the soleus muscle during prolonged immobilization.
METHODS

Animals and Experimental Design
Animal groups. Female 300-g Sprague-Dawley rats (Charles River, Wilmington, MA) were assigned to one of six groups: 1) noncasted receiving saline injections (n ϭ 10); 2) noncasted receiving the calpain inhibitor SJA-6017 (n ϭ 6); 3) noncasted receiving the caspase-3 inhibitor Ac-DEVD-CHO (n ϭ 10); 4) hindlimbs casted receiving saline (n ϭ 8); 5) hindlimbs casted receiving the calpain inhibitor SJA-6017 (n ϭ 7); and 6) casted receiving the caspase-3 inhibitor Ac-DEVD-CHO (n ϭ 8). All experiments were approved by the University of Florida Institutional Animal Care and Use Committee.
Immobilization. Gaseous isoflurane (2% for induction of anesthesia, 0.5-1.5% to maintain a surgical plane of anesthesia) was used during casting. After a surgical plane of anesthesia was reached, a layer of Medipore Dress-it (3M Health Care, St. Paul, MN) was applied to the entire area to be casted to prevent skin abrasions. A plaster-of-Paris cast (Gypsona, Reynosa, Tamaulipas, Mexico) was applied from the last rib down through both legs with the ankle plantar-flexed so as to induce maximum soleus atrophy. To prevent casted animals from damaging the cast by chewing, a single layer of fiberglass (Scotchcast Plus, St. Paul, MN) was applied on top of the plaster-of-Paris. Animals were allowed to recover from anesthesia and were monitored carefully to ensure unhindered access to food and water within their cages. Animals were removed from their cages daily to check for any damage to the cast or swelling or abrasions to the feet.
Pharmacological Inhibitors
Calpain inhibition. To inhibit calpain activity in the soleus muscle during hindlimb immobilization, we administered SJA-6017 (Calpain inhibitor IV, EMD Chemicals, Gibbstown, NJ) at a dose of 3 mg·kg body wt Ϫ1 ·day Ϫ1 . SJA-6017 was dissolved in 88% propylene, 10% ethyl alcohol, and 2% benzyl alcohol. Animals were injected subcutaneously immediately before casting and then every 24 h for 7 days.
Caspase-3 inhibition. To inhibit caspase-3 activity during hindlimb immobilization, we administered the caspase-3 inhibitor Ac-DEVD-CHO (Enzo Life Sciences, Farmingdale, NY) at a dose of 3 mg·kg body wt Ϫ1 ·day Ϫ1 . Ac-DEVD-CHO was dissolved in 0.9% sterile saline. Animals were injected subcutaneously in the neck immediately before casting and then every 24 h for 7 days.
Specificity of calpain and caspase-3 inhibition. Our laboratory has previously performed experiments inhibiting calpain activity in skeletal muscle using SJA-6017 and inhibiting caspase-3 with Ac-DEVD-CHO. In this regard, these in vitro experiments demonstrate that these inhibitors target only the intended protease without off-target effects (17) . More specifically, the calpain inhibitor SJA-6017 does not inhibit the activity of either caspase-3 or caspase-9, a caspase responsible for the activation of caspase-3. Furthermore, these data show that Ac-DEVD-CHO does not inhibit the activity of calpain-1 or calpain-2 (17) .
Antioxidant properties of the inhibitors. Because oxidative stress can promote disuse atrophy (21, 22) , we used a Trolox equivalent antioxidant capacity assay (23) to determine whether either inhibitor possessed antioxidant properties. Our results reveal that neither protease inhibitor (e.g., SJA-6017 or Ac-DEVD-CHO) quenched the oxidants used in the assay (data not shown).
Tissue Harvesting
At the completion of the experimental period, animals were again anesthetized using isoflurane. Once animals reached a surgical plane of anesthesia, both solei were removed. One soleus was divided in half, with one half frozen for cross-sectional area (CSA) analysis and the other permeabilized to measure mitochondrial function. The remaining soleus was snap frozen in liquid nitrogen and saved for Western blotting and RT-PCR analysis. Tissue was stored at Ϫ80°C until analysis. After tissue removal, animals were killed by removal of the heart.
Biochemical Measures
Preparation of permeabilized muscle fibers. We measured mitochondrial oxygen consumption in permeabilized muscle fibers as previously described (15) . Briefly, ϳ10-mg pieces of soleus muscle were teased apart on ice in cold buffer X (60 mM K-MES, 35 mM KCl, 7.23 mM K2EGTA, 2.77 mM CaK2EGTA, 20 mM imidazole, 0.5 mM DTT, 20 mM taurine, 5.7 mM ATP, 15 mM phosphocreatine, and 6.56 mM MgCl2, pH 7.1). After dissection, soleus fiber bundles were rotated in buffer X containing 50 g/ml saponin for 30 min at 4°C to permeabilize the fiber membranes. The permeabilized bundles were washed three times for 5 min by rotation in buffer Z (110 mM K-MES, 35 mM KCl, 1 mM EGTA, 5 mM K2HPO4, 3 mM MgCl2, 0.05 mM glutamate, 0.02 mM malate, and 0.5 mg/ml BSA, pH 7.1).
Measurement of mitochondrial function. Oxygen consumption by mitochondria in permeabilized soleus fibers was determined as previously described (15) . Mitochondria respired on 5 mM pyruvate and 2 mM malate. State 3 respiration was stimulated by 0.25 mM ADP. After all ADP was consumed, 10 g/ml oligomycin were added to stimulate state 4 respiration. The respiratory control ratio (RCR) was computed as the ratio of state 3 oxygen consumption to state 4 oxygen consumption.
Myofiber CSA. Pieces of soleus muscle were frozen in optimal cutting temperature medium in liquid nitrogen-cooled isopentane, as previously described (14) . Soleus sections were cut at 10 m using a cryotome (Shandon, Pittsburgh, PA) and stained for dystrophin and myosin heavy chain isoforms, as described previously (14) . Fiber CSA was determined by tracing membrane boundaries using Scion Image software (Scion, Frederick, MD). At least 100 fibers were analyzed for each animal.
Western blotting. Soleus muscles were homogenized using a motorized glass-on-glass technique with 1:10 (mg wt/l buffer) 5 mM Tris/5 mM EDTA (pH 7.5) containing protease inhibitor cocktail 1:20 (vol/vol) (Sigma-Aldrich). Following homogenization, samples were centrifuged at 1,500 g for 10 min at 4°C. Protein concentration in the supernatant was determined using the method of Bradford (2) . Equal concentrations of protein were mixed 1:1 (vol/vol) with 5% ␤-mercaptoethanol in Laemmli buffer (Bio-Rad, Hercules, CA). Membranes were probed for cleaved (active) calpain-1, cleaved caspase-3 (Cell Signaling, Danvers, MA), Bid-to-(Bid) ratio (tBid/Bid) (Imgenex, San Diego, CA), total calpain, calpastatin, and ␣-II spectrin (Santa Cruz Biotechnology, Santa Cruz, CA). Images were visualized using the Odyssey system (Licor Biosciences, Lincoln, NE). To control for protein loading and transfer differences, each protein was normalized to the level of ␣-tubulin (Santa Cruz) detected on the same membrane.
Real-time reverse transcriptase polymerase chain reaction. Messenger RNA was isolated, and cDNA synthesized, as previously described (26) . Briefly, TRIzol reagent (Life Technologies, Carlsbad, CA) was used according to the manufacturer's directions to isolate total RNA. RNA content (g/muscle) was determined by spectrophotometry. cDNA was produced using the Superscript III First Strand Synthesis System (Life Technologies). Three micrograms of RNA were reverse-transcribed using the manufacturer's protocol.
Taqman chemistry (Applied Biosystems, Foster City, CA) was used to determine the relative expression of calpastatin. The ABI Prism 7000 Sequence Detection system (Applied Biosystems) was used to perform the computed tomography method (Applied Biosystems, user bulletin no. 2, ABI PRISM 7700 Sequence Detection System). Twenty-five microliters of reactions containing 1 l of cDNA were used to determine calpastatin expression (Entrez gene ID 25403) and expression of the calibrator sample [housekeeping gene, in this case ␤-glucuronidase (Entrez gene ID 244434)]. ␤-Glucuronidase, a lysosomal glycoside hydrolase, was chosen as the reference gene based on previous work showing unchanged expression in another model of disuse atrophy, mechanical ventilation (4, 5) .
Statistical analysis. For CSA, comparisons between groups were made using two-way ANOVA with Bonferroni posttests used to determine differences in muscle fiber size between casted/noncasted animals for each of the three treatment groups. For the rest of the analysis, comparisons between groups for each dependent variable were made by a one-way analysis of variance, and, when appropriate, Tukey's honestly significant difference test was performed post hoc. Significance was established at P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS
Independent Inhibition of Calpain and Caspase-3 Prevents Casting-induced Muscle Atrophy
These experiments used a rat model of hindlimb immobilization to mimic the atrophy that occurs in humans during the casting of a limb. Analysis of the CSA of type I soleus fibers by two-way ANOVA revealed that an interaction effect exists between our casted/noncasted and drug treatment variables following 7 days of treatment. A Bonferroni posttest concluded that casting only had a significant effect in the saline-treated group (Fig. 1A) . In contrast, casting did not induce significant changes in the CSA of animals treated with either our calpain inhibitor (SJA-6017) or our caspase-3 inhibitor (Ac-DEVD-CHO), demonstrating that both calpain and caspase-3 play important roles in inactivity-induced muscle atrophy. An experimental concern with pharmacological inhibition of proteases is that prolonged protease inhibition will induce muscle hypertrophy, potentially masking atrophy. To determine whether our protease inhibitors promoted muscle hypertrophy, we treated "control" ambulatory animals with either the calpain or caspase-3 inhibitor for 7 days. We found neither an interaction effect nor main effects when analyzing our type IIA CSAs (Fig. 1B) , demonstrating that no significant changes occurred in type IIA soleus fibers in response to either daily treatment with either of our protease inhibitors, or casting. Representative muscle cross sections of all experimental groups appear in Fig. 1, C-H .
Casting Activates Calpain in the Soleus During 7 Days of Immobilization
Casting significantly increased the presence of the cleaved (active, 76 kDa) band of calpain-1 following 7 days of cast immobilization ( Fig. 2A) . Casting also significantly increased the presence of a calpain-specific cleavage product of ␣-IIspectrin that appears at 145 kDa on a Western blot of ␣-IIspectrin (Fig. 2B) . This calpain-specific cleavage fragment of ␣-II-spectrin is an index of in vivo calpain activity (30) . Daily treatment with the calpain inhibitor SJA-6017 prevented the activation of calpain-1 and the increase in the calpain-specific ␣-II-spectrin fragment, demonstrating that our inhibition of calpain activation in the soleus muscle was successful. Interestingly, independent inhibition of caspase-3 also prevented activation of calpain in the immobilized soleus muscle. The prevention of calpain activation by inhibition of caspase-3 demonstrates that caspase-3 plays a regulatory role in the activation of calpain.
Casting Activates Caspase-3 in the Soleus During 7 Days of Immobilization
Seven days of cast immobilization also significantly activated caspase-3 in the soleus muscle, demonstrated by an increase in cleaved (active) caspase-3 (Fig. 2C) . Casting also significantly increased the caspase-3-specific breakdown product of ␣-II-spectrin, a fragment of ␣-II-spectrin that can be detected at 120 kDa on a Western blot (Fig. 2D) . Importantly, treatment of animals with the caspase-3 inhibitor Ac-DEVD-CHO blunted the immobilization-induced activation of caspase-3 and completely prevented the increase in the 120-kDa product of ␣-II-spectrin in the soleus muscle. Calpain inhibition also prevented the full activation of caspase-3 and completely prevented the increase in the caspase-3-specific ␣-II-spectrin fragment, demonstrating that calpain plays a regulatory role in the activation of caspase-3. Together, these results indicate that a regulatory cross talk exists between calpain and caspase-3 in the soleus muscle during immobilization-induced fiber atrophy.
Potential Mechanism(s) Responsible for Regulatory Cross Talk Between Calpain and Caspase-3
Following the observation that a regulatory cross talk exists between calpain and caspase-3, we sought to determine the mechanism by which active calpain promotes caspase-3 activation. Evidence in nonmuscle cells indicates that calpain can cleave Bid, a proapoptotic protein, to tBid. tBid then translocates to the mitochondria, leading to the release of cytochrome c followed by caspase-3 activation (3). Similar results have been reported in diaphragm muscle during prolonged mechanical ventilation (17) . Our results reveal that immobilization of the soleus muscle results in an increase in both tBid and tBid/Bid (Fig. 3) . The change in tBid/Bid was driven by an increase in tBid, as all three casted groups demonstrated no differences in the abundance of Bid (Fig.  3B) . Importantly, this inactivity-induced increase in tBid/Bid was blunted by inhibition of calpain activity in the soleus muscle (Fig.  3C ). Although these observations do not provide definitive proof, our results are consistent with the notion that the calpain-mediated activation of caspase-3 can occur, in part, by the formation of the proapoptotic protein tBid. This is a testable hypothesis worthy of further research.
We then sought to determine the mechanism by which active caspase-3 promotes the activation of calpain. Calpastatin, the endogenous inhibitor of calpain, is a known substrate of caspase-3. Active caspase-3 may degrade calpastatin, removing calpastatin's inhibition of calpain (31) . Our results reveal that calpastatin levels decreased in the soleus muscle during prolonged immobilization (Fig. 4A) . The decline in calpastatin levels decreased the calpastatin-to-calpain ratio (calpastatin/calpain), which is an index of the ability of calpastatin to inhibit calpain. Inhibition of caspase-3 activity led to calpastatin levels statistically similar to those of both control and casted animals (Fig. 4A) . Total calpain expression was not different between any of the groups (Fig. 4B) . Similar to calpastatin expression, calpastatin/ calpain in the soleus muscle of casted animals treated with our caspase-3 inhibitor was similar to that in both control and casted animals (Fig. 4C) . Hence, our results do not provide firm evidence that caspase-3 regulates calpain activity by degrading calpastatin in limb muscles during inactivity. To ensure that casting simply was not increasing the turnover of calpastatin, we measured the mRNA expression of calpastatin. Calpastatin mRNA was decreased by casting and not rescued by either protease inhibitor (Fig. 4D) .
Inhibition of Both Calpain and Caspase-3 Protect Against Immobilization-induced Mitochondrial Dysfunction
No significant differences in oxygen consumption between groups were found during active state 3 respiration or basal state 4 respiration. However, hindlimb casting resulted in a ϳ50% decrease in the RCR of mitochondria in permeabilized fibers. Independent treatment of animals with a calpain or caspase-3 inhibitor partially prevented this decrease in mitochondrial coupling, with calpain inhibition providing a strong trend toward complete protection (P ϭ 0.056) ( Table 1) .
DISCUSSION
Overview of Major Findings
This is the first investigation to demonstrate that independent inhibition of calpain or caspase-3 in locomotor skeletal muscle is sufficient to prevent immobilization-induced type I fiber atrophy. Furthermore, our findings also reveal that a regulatory cross talk exists in limb skeletal muscle, whereby calpain and caspase-3 can activate one another. Finally, these results also provide new information about the impact of calpain and caspase-3 activation on mitochondrial function in locomotor skeletal muscle.
Independent Inhibition of Calpain or Caspase-3 Activity Prevents Immobilization-induced Soleus Muscle Atrophy
Similar to previous reports in diaphragm muscle (13, 14, 17) , the present study reveals that independent pharmacological inhibition of calpain or caspase-3 is sufficient to prevent disuse muscle atrophy. However, note that our results indicate that 7 days of limb immobilization promoted atrophy in type I fibers only, as this duration of muscle disuse was not sufficient to achieve significant atrophy in the type IIa fibers within the soleus muscle. Nonetheless, in the adult Sprague-Dawley rat, ϳ85% of the soleus fibers are type I (8), and, therefore, our Values are means Ϯ SD. Con, noncasted receiving saline injections; Cast, hindlimbs casted receiving saline; Cast-Calp, hindlimbs casted receiving the calpain inhibitor SJA-6017; Cast-Cas-3, casted receiving the caspase-3 inhibitor Ac-DEVD-CHO. Oxygen consumption (V O2) from permeabilized soleus fibers was determined during both state 3 (ADP-stimulated) and state 4 (following ADP stimulation). The respiratory control ratio (RCR) is the ratio of these two values and is a measure of mitochondrial coupling. *Significantly different vs. Con (P Ͻ 0.05). †Note that a trend toward significant differences exists between Cast and Cast-Calp, P ϭ 0.056. observed protection against disuse fiber atrophy is physiologically important.
Differences exist in the level of protection against disuse muscle atrophy between the present study, which used a highly selective pharmacological inhibitor of calpain, and previous reports using the overexpression of calpastatin to retard calpain activity. The two published reports using calpastatin overexpression to prevent calpain activation reported only partial (29) or minimal (24) protection against hindlimb suspension-induced muscle atrophy. The explanation for these divergent findings is unclear but could be due to several factors. First, the duration of muscle inactivity and the experimental model of muscle disuse differed between the present study and these earlier studies. Indeed, the present study used 7 days of immobilization to induce muscle atrophy, whereas 10 -14 days of hindlimb suspension were utilized in both of the calpastatin overexpression studies. These studies using hindlimb suspension saw greater atrophy than our casting model, which may play a role in the level or type of protease activation. Second, neither of the calpastatin overexpression investigations evaluated muscle atrophy by assessing fiber-type-specific CSAs, which may account for some of the differences between the present study and these previous reports. Additionally, the present study utilized a rat experimental model, while both calpastatin studies used a murine model to investigate disuse muscle atrophy. Finally, the study of Tidball and Spencer (29) acknowledges that they did not achieve complete inhibition of calpain activity in skeletal muscle, whereas our data (Fig. 2B , ␣-II-spectrin levels) indicate that the calpain activity in the soleus muscle of our casted animals receiving the calpain inhibitor did not differ from the calpain activity in the soleus muscle of an ambulatory control animal.
Importantly, our results also reveal that pharmacological inhibition of caspase-3 provides protection against immobilization-induced muscle atrophy in type I fibers of the soleus muscle. Similar results have been reported in ventilator-induced atrophy of diaphragm muscle (14, 17) . Moreover, a recent report also concluded that denervation-induced gastrocnemius muscle atrophy is diminished in caspase-3 knockout mice (18) . However, the present experiment reveals that caspase-3 inhibition results in complete protection against disuse-induced soleus muscle atrophy, whereas Plant et al. (18) report only a modest reduction in gastrocnemius muscle atrophy in the wild-type vs. the caspase-3 knockout mice. The explanation for these divergent findings is unclear, but species differences, duration of experiment, fiber-type differences between gastrocnemius and soleus muscles, and/or differences in atrophy model (i.e., denervation vs. immobilization) could be responsible for these disparities.
Regulatory Cross Talk Exists Between Calpain and Caspase-3
Our data provide the first evidence that a regulatory cross talk exists between calpain and caspase-3, as inhibition of calpain is sufficient to prevent activation of caspase-3 in limb skeletal muscle. Similarly, inhibition of caspase-3 prevented calpain activation in the inactive soleus muscle. To investigate the mechanism responsible for these findings, we tested the hypothesis that calpain can potentially activate caspase-3 through cleavage of Bid to form tBid. tBid is a membrane pore-forming protein that can release cytochrome c from the mitochondria, resulting in the subsequent activation of caspase-3 (3). Our results reveal that inhibition of calpain activity results in a significant attenuation of the immobilization-induced increase in tBid/Bid in the soleus muscle (Fig.  3C) . Thus it is feasible that calpain activates caspase-3 in skeletal muscle disuse atrophy via a tBid-dependent mechanism. Nonetheless, this evidence is not definitive, as active caspase-3 can also lead to Bid cleavage, leading to a feedforward activation of caspase-3 (25) . Therefore, additional work will be required to determine the specific mechanism(s) by which active calpain promotes caspase-3 activation.
To investigate the mechanism responsible for the caspase-3-mediated activation of calpain, we measured the protein abundance of both calpain and the endogenous calpain inhibitor, calpastatin. In this regard, our laboratory's prior work revealed that caspase-3 inhibition prevented the decrease in calpastatin and calpastatin/calpain associated with mechanical ventilation induced diaphragm atrophy (17) . The present experiments also demonstrate that caspase-3 inhibition blunts the casting-induced decrease in calpastatin levels in the soleus muscle (Fig. 4A) , and either calpain inhibition or caspase-3 inhibition is sufficient to provide very modest protection against immobilization-induced decreases in calpastatin/calpain (Fig. 4C) . Nonetheless, because the inhibition of caspase-3 does not completely prevent the immobilizationinduced decrease in both calpastatin and calpastatin/calpain in the soleus muscle, it is possible that caspase-3-mediated activation of calpain may involve other mechanisms in skeletal muscle exposed to long periods of inactivity. An important difference between the present study and our laboratory's previous work (17) in diaphragm muscle is the duration of muscle inactivity. Indeed, Nelson et al. (17) investigated mechanical ventilation-induced diaphragm atrophy following only 12 h of inactivity, while the present study investigated limb muscle atrophy following 7 days of immobilization. Thus caspase-3 inhibition may be sufficient to prevent calpastatin degradation in skeletal muscle in the short term, but this may not be an important protective mechanism over longer time periods. Supporting this prediction is the observation that a decrease in calpastatin gene expression following 7 days of casting was not rescued by either calpain or caspase-3 inhibition (Fig. 4D) .
Protection of Mitochondrial Function by Protease Inhibition
Prolonged muscle inactivity is associated with mitochondrial dysfunction in both limb and diaphragm muscle (11, 15, 20) . Consistent with previous findings, the present investigation shows that 7 days of immobilization induced a significant decrease in the RCR of mitochondria in permeabilized soleus fibers (Table 1) . RCR is an index of mitochondrial coupling, and a decrease in RCR indicates that mitochondria in the casted muscle are less coupled than mitochondria within the soleus muscles of weight-bearing animals. Interestingly, caspase-3 inhibition prevented a significant decline in mitochondrial function, and inhibition of calpain activity in the soleus muscle almost completely rescued the immobilization-induced decline in the mitochondrial RCR. Although our experiments do not provide a mechanism to explain this observation, one potential explanation is that calpain-10, a mitochondrial calpain linked to mitochondrial dysfunction (1), might be inhibited by our calpain inhibitor. If this is the case, prevention of calpain-10 activation could protect mitochondrial electron transport chain proteins from degradation and thus preserve mitochondrial function. This is another testable hypothesis worthy of future experimentation.
Conclusions
In conclusion, this study revealed that inhibition of either calpain or caspase-3 is sufficient to prevent casting-induced atrophy of the soleus, providing evidence that both calpain and caspase-3 are important proteases in disuse limb muscle atrophy. Furthermore, we have demonstrated for the first time in limb muscle that a regulatory cross talk exists between calpain and caspase-3, whereby calpain can stimulate caspase-3 activation, and active caspase-3 can promote calpain activation. Finally, our results reveal that active calpain and, to a lesser extent, active caspase-3 can promote mitochondrial uncoupling in skeletal muscle. The mechanism(s) responsible for this finding is unknown and warrants further research.
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